ClinicalTrials.gg
WithdrawnNCT06205290Updated Apr 2, 2024

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

A Phase 3 interventional study of Liso-cel and Idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Withdrawn at 48 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Business objectives have changed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb — 1 open to participants now, 3 under way, none of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Bristol-Myers Squibb.

Enrollment
20th of 21
0 · median 47
Started
2024
the only one that year
Phase 3
3 of 25
none open now
Registered
24th of 25
by date

Among the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb, this one is the 20th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 3, and was the 24th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of liso-cel vs Investigator's Choice options (idelalisib + rituximab or bendamustine + rituximab) in adult participants with R/R CLL or SLL, whose disease has failed treatment with both BTKi and BCL2i targeted therapies.

03

Conditions studied

  • Leukemia, Lymphocytic, Chronic, B-Cell

Keywords

  • Small Lymphocytic lymphoma
  • B cell malignancies
  • CD19+ B cell malignancies
  • Non-Hodgkin lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have what doctors call , which will be evaluated before each participant take part of the study.
  • Must have received both a BTKi and a BCL2i treatment, and their disease must have come back or not responded to treatment, or they must not have been able to tolerate the side-effects of the BTKi and/or BCL2i treatment(s).
  • Must also have an performance score of 0 or 1, which means they are able to carry out their normal daily activities without any problems.

Exclusion criteria

Exclusion Criteria

  • Heart problems.
  • Bleeding disorders.
  • Active cancer in their brain.
  • Other reasons include:.

    i) Having certain treatments in the past.

ii) Having certain infections that are not under control.

iii) Having certain brain conditions.

  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm A: Liso-cel Monotherapy

    Biological: Liso-cel · Drug: Fludarabine · Drug: Cyclophosphamide

  • Active comparator
    Arm B: Investigator's Choice

    Drug: Idelalisib · Drug: Rituximab · Drug: Bendamustine

Interventions

  • BiologicalLiso-cel

    Specified dose on specified days

    Also known as: JCAR017, Breyanzi®, BMS-986387, lisocabtagene maraleucel

  • Specified dose on specified days

    Also known as: Zydelig®

  • Specified dose on specified days

    Also known as: Rituxan®, Mabthera®, Riximyo®, Truxima®

  • Specified dose on specified days

    Also known as: Bendeka®, Treanda®, Belrapzo®

  • Specified dose on specified days

    Also known as: Fludara®, Bendarabin®

  • Specified dose on specified days

    Also known as: Endoxan®, Cytoxan®

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) per independent review committee (IRC) assessment

    Time frame: Up to 5 years from the last participant randomized

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to 5 years from the last participant randomized

  2. Complete Response Rate (CRR) per IRC assessment

    Time frame: Up to 5 years from the last participant randomized

  3. CRR per investigators' assessment

    Time frame: Up to 5 years from the last participant randomized

  4. Complete response with incomplete bone marrow recovery (CRi)

    Time frame: Up to 5 years from the last participant randomized

  5. Minimal residual disease (MRD)-negativity rate

    Time frame: Up to 5 years from the last participant randomized

  6. Overall Response Rate (ORR) per IRC assessment

    Time frame: Up to 5 years from the last participant randomized

  7. ORR per investigators' assessment

    Time frame: Up to 5 years from the last participant randomized

  8. Duration of Response (DOR) per IRC assessment

    Time frame: Up to 5 years from the last participant randomized

  9. Duration of Complete Response (DOCR) per IRC assessment

    Time frame: Up to 5 years from the last participant randomized

  10. PFS per investigators' assessment

    Time frame: Up to 5 years from the last participant randomized

  11. Progression post next line of treatment (PFS-2)

    Time frame: Up to 5 years from the last participant randomized

  12. Number of participants with Adverse Events (AEs)

    Time frame: Up to 5 years from the last participant randomized

  13. Number of participants with Adverse Events of Special Interest (AESIs)

    Time frame: Up to 5 years from the last participant randomized

  14. Number of participants with laboratory abnormalities

    Time frame: Up to 5 years from the last participant randomized

  15. Time from randomization to first confirmed clinically meaningful improvement from baseline in the European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30)

    The following domains on the EORTC QLQ-C30 will be assessed: * Fatigue * Physical functioning * Role functioning * Cognitive functioning * Global health status/quality of life (GHS/QoL)

    Time frame: Up to 5 years from the last participant randomized

  16. Time from randomization to first confirmed clinically meaningful improvement from baseline in the European Quality of Life Module Chronic Lymphocytic Leukemia 17 (EORTC QLQ-CLL17)

    The following domains on the EORTC QLQ-CLL17 will be assessed: * Symptom burden * Physical condition/fatigue

    Time frame: Up to 5 years from the last participant randomized

  17. Mean changes from baseline in the following key health-related quality of life (HRQoL) domains: GHS/QoL

    As assessed by EORTC QLQ-C30

    Time frame: Up to 5 years from the last participant randomized

  18. Mean changes from baseline in the following key HRQoL domains: Fatigue

    As assessed by EORTC QLQ-C30

    Time frame: Up to 5 years from the last participant randomized

  19. Mean changes from baseline in the following key HRQoL domains: Physical functioning

    As assessed by EORTC QLQ-C30

    Time frame: Up to 5 years from the last participant randomized

  20. Mean changes from baseline in the following key HRQoL domains: Role functioning

    As assessed by EORTC QLQ-C30

    Time frame: Up to 5 years from the last participant randomized

  21. Mean changes from baseline in the following key HRQoL domains: Cognitive functioning

    As assessed by EORTC QLQ-C30

    Time frame: Up to 5 years from the last participant randomized

  22. Mean changes from baseline in the following key HRQoL domains: Symptom burden

    As assessed by EORTC QLQ-CLL17

    Time frame: Up to 5 years from the last participant randomized

  23. Mean changes from baseline in the following key HRQoL domains: Physical condition/fatigue

    As assessed by EORTC QLQ-CLL17

    Time frame: Up to 5 years from the last participant randomized

07

Study locations

48 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Local Institution - 0023
    Duarte, California 91010, United States
  • University of California Davis (UC Davis) Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • Local Institution - 0120
    Atlanta, Georgia 30322, United States
  • St. Luke's Mountain States Tumor Institute : Boise
    Boise, Idaho 83712, United States
  • Local Institution - 0058
    Iowa City, Iowa 52242, United States
  • Local Institution - 0048
    Saint Matthews, Kentucky 40207, United States
  • Local Institution - 0101
    Minneapolis, Minnesota 55455, United States
  • Local Institution - 0121
    New York, New York 10029, United States
  • Stony Brook University
    Stony Brook, New York 11794, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45242, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • St. David's South Austin Medical Center
    Austin, Texas 78704, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Local Institution - 0068
    Morgantown, West Virginia 26506, United States
  • University Hospital and UW Health Clinics
    Madison, Wisconsin 53792, United States
  • Local Institution - 0094
    Salzburg, 5020, Austria
  • Local Institution - 0093
    Wien, 1090, Austria
  • Local Institution - 0113
    Yvoir, Namur 5530, Belgium
  • Local Institution - 0112
    Leuven, Vlaams-Brabant 3000, Belgium
  • Local Institution - 0122
    Rennes, Bretagne 35033, France
  • Local Institution - 0036
    Montpellier, Languedoc-Roussillon 34295, France
  • Local Institution - 0038
    Lyon, Rhône-Alpes 69008, France
  • Local Institution - 0035
    Clermont-Ferrand, 63100, France
  • Local Institution - 0037
    Paris, 75013, France
  • Local Institution - 0034
    Toulouse, 31100, France
  • Local Institution - 0084
    Dresden, Sachsen 01307, Germany
  • Local Institution - 0081
    Leipzig, Sachsen 04103, Germany
  • Local Institution - 0083
    Kiel, Schleswig-Holstein 24105, Germany
  • Local Institution - 0079
    Heidelberg, D-69120, Germany
  • Local Institution - 0082
    Köln, 50937, Germany
  • Local Institution - 0080
    Ulm, 89081, Germany
  • Local Institution - 0091
    Milan, Milano 20162, Italy
  • Local Institution - 0088
    Bologna, 40138, Italy
  • Local Institution - 0114
    Amsterdam, Noord-Holland 1105 AZ, Netherlands
  • Local Institution - 0117
    Groningen, 9713 GZ, Netherlands
  • Local Institution - 0073
    Oslo, 0372, Norway
  • Local Institution - 0104
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Local Institution - 0105
    L'Hospitalet Del Llobregat, Barcelona [Barcelona] 08908, Spain
  • Local Institution - 0107
    Santander, Cantabria 39008, Spain
  • Local Institution - 0108
    Madrid, Madrid, Comunidad De 28034, Spain
  • Local Institution - 0106
    Valencia, Valenciana, Comunitat 46010, Spain
  • Local Institution - 0103
    Salamanca, 37007, Spain
  • Local Institution - 0071
    Huddinge, 141 86, Sweden
  • Local Institution - 0115
    London, London, City Of NW1 2PG, United Kingdom
  • Local Institution - 0109
    London, London, City Of SE5 9RS, United Kingdom
  • Local Institution - 0111
    Leeds, LS9 7TF, United Kingdom
  • Local Institution - 0110
    Oxford, 0X3 7LE, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2024; primary completion for Oct 2031, 92 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 16, 2024
StartEst.
Jan 16, 2024
Primary completionEst.
Oct 13, 2031
CompletionEst.
Oct 13, 2031
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06205290
Collaborators
Celgene Corporation
Responsible party
Sponsor
First posted
Jan 16, 2024
Start date
Jan 16, 2024 (estimated)
Primary completion
Oct 13, 2031 (estimated)
Completion
Oct 13, 2031 (estimated)
Last update
Apr 2, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisocabtagene maraleucel

Start the discussion